Use of AZT in antiretroviral therapy (ART) is associated with subcutaneous adipose tissue (SAT) and mitochondrial toxicity (MtTox). However, detailed molecular analyses of the additional contribution of protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) to this toxicity are lacking.
In a prospective cohort study, ART-naïve HIV+ subjects initiating ART containing AZT/PI, AZT/NNRTI or non-AZT/non-PI underwent assessments of clinical, demographic parameters and limb fat (LF) by DXA at wks 0, 12, 24 and 48. Mitochondrial DNA (mtDNA) and expression of 55 key insulin signalling, lipid metabolism and mitochondrial function genes were measured by qPCR in fasting SAT biopsies from wks 0, 2 and 48. Associations between treatment groups and parameter changes were analysed by adjusted longitudinal marginal models, gene expression by LIMMA in R, with data presented as model parameter estimates (PE [95% CI]).
23 subjects were recruited, median [IQR] age 39 [34, 48] yrs, 91% Caucasian, 87% male, CD4+ count 132 [58, 228] cells/mm3, log HIVRNA 4.97 [4.51, 5.57] cps/ml. Over 48 weeks, LF increased as expected with non-AZT/non-PI ART (+30.5 [+11.9, +49.1] g/wk) with significantly lower LF gains in the AZT/PI and AZT/NNRTI groups (-15.7 [-45.7, +14.2], P=0.005 and +4 [-29.3, +21.3] g/wk, P=0.012 respectively). Initiation of ART led to decreased expression of inflammatory genes in groups overall, including CCL2 (P=0.017) and IL6 (P=0.017, P=0.033). The largest mtDNA decreases occurred with AZT/NNRTI ART (-10.2 [-20, -0.6] cps/cell/wk), being significantly greater than both AZT/PI and non-AZT/non-PI ART groups (P.E. +3.2 [-8, +14.3], P=0.001 and +2.2 [-5.2, +9.5], P=0.015 respectively, fig.1). Consistent with MtTox, this group also had upregulated expression of the mitochondrial biogenesis gene TFAM (P=0.012) and decreases in key metabolic genes LEP and INSR at week 48 (P=0.013 and P=0.049 respectively), none of which were observed in the other two groups. In fact expression of several key adipocyte genes increased at week 48; PPARG and FABP4 with AZT/PI (P=0.021 and P=0.001) and Adiponectin with non-AZT/non-PI (P=0.006).
These data suggest greater SAT MtTox with AZT/NNRTI ART than either AZT/PI or non-AZT/non-PI. However, changes in LF did not differ significantly between AZT-treated groups. These findings support emerging data on NNRTIs contribution to thymidine-NRTI toxicity, suggesting additive MtTox as an underlying mechanism.